ERBB2 and breast cancer: The combination of T-DM1 and atezolizumab was further tested in the phase II KATE 2 trial, where patients with metastatic HER2+ BC were randomized (2:1) to receive either T-DM1 plus atezolizumab or T-DM1 plus placebo.